Biodesix is a pioneer in enabling personalized medicine by focusing on the unique characteristics of the patient using mass spectrometry based molecular diagnostics. By rapidly and cost-effectively analyzing the concurrent presence of many proteins in patient samples, Biodesix's products will improve the ability of physicians to provide treatment tailored specifically to a patient.

Biodesix has focused on applying signal processing, statistical analysis, and an in-depth understanding of the physics of mass spectrometers to build a bio-analysis platform that can be used to develop diagnostic "classifiers" for use by researchers, drug developers and clinicians. These classifiers can reproducibly, reliably, and with clinically significant accuracy, predict and evaluate normal biologic or pathogenic states or the probable pharmacological responses to a therapeutic intervention.

Biodesix, using its research platform, is developing diagnostic products for the non-invasive early detection of disease, for stratifying patient populations to improve therapeutic treatment (distinguishing between potential patients who will benefit from a particular treatment from those who will not), and to provide technically simple means for continuous disease monitoring. Biodesix's first product,VeriStrat™, is a simple blood test which is able to separate patients into groups with statistically different prognoses when receiving second-line treatment using inhibitors to the epidermal growth factor receptor (EGFR) such as gefitinib (Iressa, AstraZeneca) and erlotinib (Tarceva, OSI/Genentech/Roche). It is the first mass spectrometry diagnostic that uses multiple markers and which has been shown to be clinically reproducible.

The Company has developed a set of tools and a methodology - the ProTS Platform - for the analysis and creation of classifiers using specific features from MS spectra. Its unique benefits compared to other diagnostic discovery and development techniques lie in the speed with which viable classifiers can be discovered and clinically validated. Further, it works with a variety of clinical specimens, requires little (or no) sample pre-treatment, and is consistently reproducible (with Biodesix's tools). Finally, the cost and time to perform the tests in a clinical setting is relatively inexpensive. As a result, from discovery through to the clinical use of the test, the ProTS Platform - and diagnostic products developed with it - have very attractive cost and time advantages over competing techniques in the area of molecular diagnostics, and provides the first validated platform translating bench science to bedside use.